Intra-lysosomal peptide assembly for the high selectivity Index against cancer
A groundbreaking anticancer treatment technology that selectively targets cancer cell lysosomes and overcomes drug resistance has been developed by Professor Ja-Hyoung Ryu and his research team in the Department of Chemistry at UNIST. This pioneering research promises a new paradigm for chemical anticancer drugs in the future.
Lysosomes are crucial organelles responsible for breaking down and recycling cellular components. Targeting lysosomes with anticancer drugs has emerged as a promising approach to combat drug resistance in cancer cells. However, ...













